Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Yan Lou

Showing results (341-350 of 346) with videos related to

Pageof 35
Sort By:
You have reached the last page of results.This site can display upto 346 results.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|May 13, 2026
Efficacy and Safety of Camrelizumab Plus Apatinib in Patients With Refractory Chordoma: A Phase II Clinical TrialCheng Yang, Qi Jia, Chenglong Zhao, et al.
Immunological Investigations|May 7, 2002
Immunogene therapy of tumors with a vaccine based on the ligand-binding domain of chicken homologous integrin beta3Yan-Yan Lou, Yu-Quan Wei, Li Yang, et al.
Journal of Medicinal Chemistry|October 3, 2013
Benzazepinones and benzoxazepinones as antagonists of inhibitor of apoptosis proteins (IAPs) selective for the second baculovirus IAP repeat (BIR2) domainAndrew F Donnell, Christophe Michoud, Kenneth C Rupert, et al.
Journal of Medicinal Chemistry|October 8, 2013
Optimization of benzodiazepinones as selective inhibitors of the X-linked inhibitor of apoptosis protein (XIAP) second baculovirus IAP repeat (BIR2) domainRobert F Kester, Andrew F Donnell, Yan Lou, et al.
Journal of Medicinal Chemistry|May 31, 2017
Design and Discovery of N-(2-Methyl-5'-morpholino-6'-((tetrahydro-2H-pyran-4-yl)oxy)-[3,3'-bipyridin]-5-yl)-3-(trifluoromethyl)benzamide (RAF709): A Potent, Selective, and Efficacious RAF Inhibitor Targeting RAS Mutant CancersGisele A Nishiguchi, Alice Rico, Huw Tanner, et al.
Journal of Medicinal Chemistry|May 7, 2019
Design and Discovery of <i>N</i>-(3-(2-(2-Hydroxyethoxy)-6-morpholinopyridin-4-yl)-4-methylphenyl)-2-(trifluoromethyl)isonicotinamide, a Selective, Efficacious, and Well-Tolerated RAF Inhibitor Targeting RAS Mutant Cancers: The Path to the ClinicSavithri Ramurthy, Benjamin R Taft, Robert J Aversa, et al.
Pageof 35

Showing results (341-350 of 346) with videos related to

Sort By:
Pageof 35
You have reached the last page of results.This site can display upto 346 results.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|May 13, 2026
Efficacy and Safety of Camrelizumab Plus Apatinib in Patients With Refractory Chordoma: A Phase II Clinical TrialCheng Yang, Qi Jia, Chenglong Zhao, et al.
Immunological Investigations|May 7, 2002
Immunogene therapy of tumors with a vaccine based on the ligand-binding domain of chicken homologous integrin beta3Yan-Yan Lou, Yu-Quan Wei, Li Yang, et al.
Journal of Medicinal Chemistry|October 3, 2013
Benzazepinones and benzoxazepinones as antagonists of inhibitor of apoptosis proteins (IAPs) selective for the second baculovirus IAP repeat (BIR2) domainAndrew F Donnell, Christophe Michoud, Kenneth C Rupert, et al.
Journal of Medicinal Chemistry|October 8, 2013
Optimization of benzodiazepinones as selective inhibitors of the X-linked inhibitor of apoptosis protein (XIAP) second baculovirus IAP repeat (BIR2) domainRobert F Kester, Andrew F Donnell, Yan Lou, et al.
Journal of Medicinal Chemistry|May 31, 2017
Design and Discovery of N-(2-Methyl-5'-morpholino-6'-((tetrahydro-2H-pyran-4-yl)oxy)-[3,3'-bipyridin]-5-yl)-3-(trifluoromethyl)benzamide (RAF709): A Potent, Selective, and Efficacious RAF Inhibitor Targeting RAS Mutant CancersGisele A Nishiguchi, Alice Rico, Huw Tanner, et al.
Journal of Medicinal Chemistry|May 7, 2019
Design and Discovery of <i>N</i>-(3-(2-(2-Hydroxyethoxy)-6-morpholinopyridin-4-yl)-4-methylphenyl)-2-(trifluoromethyl)isonicotinamide, a Selective, Efficacious, and Well-Tolerated RAF Inhibitor Targeting RAS Mutant Cancers: The Path to the ClinicSavithri Ramurthy, Benjamin R Taft, Robert J Aversa, et al.
Pageof 35